Is Symbiox Investme overvalued or undervalued?

As of 7 November 2025, the valuation grade for Symbiox Investme has moved from fair to expensive, indicating that the company is overvalued. The current PE ratio stands at 36.70, while the PEG ratio is notably low at 0.23, suggesting that despite high earnings expectations, the stock price may not be justified. Furthermore, the EV to EBITDA ratio is at -4.23, which raises concerns about the company's operational efficiency and profitability.
In comparison to its peers, Bajaj Finance has a PE ratio of 38.09 and is classified as very expensive, while Life Insurance is rated very attractive with a PE of 11.44. This stark contrast highlights that Symbiox Investme's valuation is not supported by strong fundamentals relative to its competitors. Additionally, the company's recent stock performance shows a year-to-date decline of 43.73%, significantly underperforming the Sensex, which has gained 6.50% in the same period. Overall, these indicators suggest that Symbiox Investme is overvalued in the current market environment.